Immunogenicity of the UK group B meningococcal vaccine (4CMenB) schedule against groups B and C meningococcal strains (Sched3): outcomes of a multicentre, open-label, randomised controlled trial
This study (n=213) reports the first immunogenicity data for the reduced dose, with at least 86% of participants having human complement serum bactericidal antibody titres above the correlate of protection for the three MenB strains tested, both post-priming and post-boost.
Source:
The Lancet Infectious Diseases
SPS commentary:
The authors say their results “provide reassurance that the changes to the PCV13 schedule in the UK national immunisation programme, with a reduction from 2 + 1 (given at 2, 4, and 12 months of age) to 1 + 1 (given at 3 and 12 months of age) doses, will not alter the immunogenicity of 4CMenB or other concomitant routine vaccines.” They do however note that there was an unexpected reduction in bactericidal antibodies against MenC, suggesting that ongoing surveillance for re-emergent MenC disease is important.